ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
ImmunityBio, Inc. (IBRX)
Company Research
Source: Business Wire
Dr. Soon-Shiong joins Nobel laureates, former NIH directors, and leading oncology pioneers in Washington, D.C. to chart a path toward defeating cancer by 2035, with the discussion streamed live at Cancer 2035: A Roadmap for the Future Summit CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (Nasdaq: IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive Chairman, and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, will participate as a featured speaker at "Cancer 2035: A Roadmap for the Future," a landmark summit co-hosted by the Milken Institute and the Richard Nixon Foundation in Washington, D.C. on February 23–24, 2026.The event coincides with the 55th anniversary of the National Cancer Act, the landmark legislation signed by President Richard Nixon that transformed the nation’s approach to cancer research and set in motion decades of scientific and clinical progress. The
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio's ANKTIVA Approvals Broaden Global Reach And Investor Opportunity [Yahoo! Finance]Yahoo! Finance
- ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- ImmunityBio (NASDAQ:IBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- ImmunityBio: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- 2/24/26 - Form 4
- IBRX's page on the SEC website